Compare Merck & Co., Inc. (MRK) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Sezzle Inc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Sezzle Inc trades at $128.64 (market cap $3.95B). The key difference: Merck & Co., Inc. is far larger — about 88.9× Sezzle Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Sezzle Inc for 15 Days on average.
| MRK | SEZL | |
|---|---|---|
Market Cap | $351.28B | $3.95B |
Volume | 7,969,665 | 550,075 |
Sector | Health | Financials |
52-Week High | $156.43 | $188.55 |
52-Week Low | $82.49 | $50.97 |
Typical Hold Time | 98 Days | 15 Days |
Enterprise Value | $398.04B | $3.99B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
SEZL stock is trading at $128.64, up 12.99% in the past 24 hours, showing strong momentum with a bullish technical signal. The company demonstrates exceptional profitability with 72.36% gross margins and 30.35% net income margins, while recent earnings have consistently beaten expectations. Analyst consensus remains strongly positive with a $168 price target representing significant upside potential from current levels.
SEZL presents a compelling growth opportunity with robust financial metrics and strong analyst support, though investors should monitor competitive pressures in the BNPL sector and the stock's current technical overbought conditions. The company's expanding product portfolio and subscriber growth provide fundamental support for continued appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
